This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
While the immune system can eliminate cancer, it can also contribute to cancer growth under certain conditions. HMGB1 is an important immune molecule that plays a role in this process and may have immense value in the clinic. Dr. Bassi wants to understand more about its activity, so he’s analyzing tumor-immune interactions in a mouse cancer model and determining how differential HMGB1 activity influences breast cancer progression as well as responses to immunotherapy and chemotherapy. In this way, he hopes to reveal insights about new targets that guide new approaches to improve patient outcomes.
University Health Network (Canada) | Breast Cancer | 2016 | Tak W. Mak, Ph.D.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
This September for Childhood Cancer Awareness Month, we look at new research, new treatments, and how we are working toward a future immune to childhood cancer.
This September for Gynecologic Cancer Awareness Month, we reflect on new treatments, research discoveries, and how CRI is making its impact on a future immune to cervical, ovarian, and uterine cancers.